Education
About Us
Working with TipRanks
Follow Us
Trisalus Life Sciences, Inc. (TLSI)
NASDAQ:TLSI
TLSI Stock Chart & Stats
$4.62
-$0.05(-0.97%)
At close: 4:00 PM EST
$4.62
-$0.05(-0.97%)
Day’s Range― - ―
52-Week Range$3.42 - $7.95
Previous CloseN/A
Volume4.84K
Average Volume (3M)186.05K
Market Cap
$282.93M
Enterprise Value$188.96M
Total Cash (Recent Filing)$20.44M
Total Debt (Recent Filing)$34.44M
Price to Earnings (P/E)―
Beta0.66
Next Earnings
May 14, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding61,306,440
10 Day Avg. Volume237,996
30 Day Avg. Volume186,046
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)-7.81
Price to Sales (P/S)5.86
P/FCF Ratio-13.97
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue4.19
Enterprise Value/Gross Profit4.95
Enterprise Value/Ebitda-6.74
Forecast
1Y Price Target
$10.13Price Target Upside119.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.36
Revenue Forecast (FY)$61.50M
Bulls Say, Bears Say
Bulls Say
Commercial ExpansionCapital raised through recent equity transactions funds a plan to roughly double the sales force, which should broaden market coverage and support a faster rollout of TriNav.
Product Compatibility And AdoptionA new TriNav product designed to work with standard microcatheter systems could allow interventional radiologists to use preferred tools and expand the device's use across additional procedure types, driving incremental procedure-related sales.
Total Addressable Market ExpansionExpansion into indications such as multinodular goiter and uterine fibroid embolization expands the company's addressable market to an estimated $2.5 billion and creates multiple potential revenue pathways.
Bears Say
Cash Burn And Profitability VisibilityPlans to scale commercial infrastructure without explicit profitability guidance raise cash burn and reduce near-term visibility into when the company will achieve sustained profitability.
Product Uptake And Revenue VariabilityModest initial market reception to recent product launches and a multi-month ramp for new sales hires create uneven revenue patterns and contributed to guidance that fell short of analyst expectations.
Share DilutionOutstanding warrants, restricted stock units and stock options, together with recent equity raises, increase potential share count and could dilute existing shareholders' ownership and per-share metrics.
TriSalus Life Sciences News
TLSI FAQ
What was Trisalus Life Sciences, Inc.’s price range in the past 12 months?
Trisalus Life Sciences, Inc. lowest stock price was $3.42 and its highest was $7.95 in the past 12 months.
What is Trisalus Life Sciences, Inc.’s market cap?
Trisalus Life Sciences, Inc.’s market cap is $282.93M.
When is Trisalus Life Sciences, Inc.’s upcoming earnings report date?
Trisalus Life Sciences, Inc.’s upcoming earnings report date is May 14, 2026 which is in 63 days.
How were Trisalus Life Sciences, Inc.’s earnings last quarter?
Trisalus Life Sciences, Inc. released its earnings results on Mar 05, 2026. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.142 by -$0.068.
Is Trisalus Life Sciences, Inc. overvalued?
According to Wall Street analysts Trisalus Life Sciences, Inc.’s price is currently Undervalued.
Does Trisalus Life Sciences, Inc. pay dividends?
Trisalus Life Sciences, Inc. does not currently pay dividends.
What is Trisalus Life Sciences, Inc.’s EPS estimate?
Trisalus Life Sciences, Inc.’s EPS estimate is -0.13.
How many shares outstanding does Trisalus Life Sciences, Inc. have?
Trisalus Life Sciences, Inc. has 61,306,440 shares outstanding.
What happened to Trisalus Life Sciences, Inc.’s price movement after its last earnings report?
Trisalus Life Sciences, Inc. reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.142. Following the earnings report the stock price went down -6.394%.
Which hedge fund is a major shareholder of Trisalus Life Sciences, Inc.?
Currently, no hedge funds are holding shares in TLSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TriSalus Life Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.13 (119.26% Upside)
$10.13 (119.26% Upside)
Blogger Sentiment
Bullish
TLSI Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 68.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.89%
12-Months-Change
Fundamentals
Return on Equity
137.18%
Trailing 12-Months
Asset Growth
47.39%
Trailing 12-Months
Company Description
Trisalus Life Sciences, Inc.
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
TLSI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong commercial momentum and sizable top-line growth (Q4 revenue +60% YoY; FY revenue +53%), improved quarterly profitability metrics (higher gross margin and much smaller adjusted EBITDA loss), successful product launches and an oversubscribed $46M financing to fund an aggressive commercial and clinical expansion. Notable negatives include a delayed nelitolimod data release (rescheduled to H2 2026), earlier-year manufacturing inefficiencies that modestly pressured full-year gross margin, higher one-time G&A charges, a worse GAAP loss per share due to capital structure changes, and near-term execution/timing risk as the company ramps its enlarged sales organization. Overall, the positive commercial and financing developments and improving operating performance outweigh the timing and one-time challenges, supporting a favorable outlook while acknowledging execution risk tied to the expansion and product clearance timing.View all TLSI earnings summariesTLSI Stock 12 Month Forecast
Average Price Target
$10.13
▲(119.26% Upside)
Technical Analysis
Ownership Overview
18.51% Insiders
3.30% Mutual Funds
9.21% Other Institutional Investors
64.36% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---